ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab (NCT06876714)
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Who can join: Review the eligibility criteria below.
Location: Cancer Center at Saint Joseph's — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (684 Sites)
Showing the first 25 of 684 sites.
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
- Kaiser Permanente Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
- Stanford Cancer Center Emeryville — Emeryville, California
- Kaiser Permanente-Fremont — Fremont, California
- Washington Health — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Loma Linda University Medical Center — Loma Linda, California
- Fremont - Rideout Cancer Center — Marysville, California
- Mercy Cancer Center — Merced, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente-Oakland — Oakland, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
📞 Contact the Study Coordinator
Phone: (773) 702-9171
Email: breastprotocols@alliancenctn.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anatomic Stage I Breast Cancer AJCC v8
- Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study — Kingman, Arizona
- Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy — Houston, Texas
- Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer — Antioch, California
- Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer — Houston, Texas
- Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer — Houston, Texas
- Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients — Scottsdale, Arizona
Explore by condition: All Anatomic Stage I Breast Cancer AJCC v8 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.